Global insights for smarter market access strategies

MAESTrO brings together global market access submission and outcome insights, to help you introduce new medical technologies more efficiently.

Play video Newsletter signup Download brochure Contact us

Intelligent market access

MAESTrO integrates years of market access submissions and outcomes from all the world’s major health technology assessment (HTA) agencies.

Global perspective

We cover all major HTA markets to provide global, regional and local market access intelligence.

Expert delivery

Our data and interface are 
constantly fine-tuned by highly experienced industry analysts.

One-stop service

We gather and organise all the essential data in one place, so 
our solution is all you need.

You’ll be in good company

Real benefits

By combining, analysing and correlating complex data into a one-stop resource, MAESTrO can help you mitigate the costs, delays and risks of medical technology development. Use our data, analysis and platform to:

Gain valuable insights

into successful submission strategies, and benchmark outcomes against competitors.

Compare decisions

between regions and agencies, and assess the effect of past or planned policies.

Compare technologies

for their proposed benefits and potential to be subsidised by the local authority.

Analyse opportunities

based on past successes, emerging technologies, and potential competition.

Global coverage

MAESTrO offers you simple access to a world of correlated submission and outcome data.

  • Agencies
    17
  • Countries
    33
  • Entries
    22,241
  • Technologies
    7,826
  • Diseases
    3,002
  • Companies
    2,907
Switzerland (Swiss Medic)
  • Type: Registration
  • Entries: 264
  • Diseases: 95
  • Technologies: 173
  • Companies: 78
Scotland (SMC)
  • Type: Reimbursement
  • Entries: 2012
  • Diseases: 255
  • Technologies: 717
  • Companies: 200
New Zealand (PHARMAC)
  • Type: Reimbursement
  • Entries: 919
  • Diseases: 195
  • Technologies: 373
  • Companies: 135
England (Cancer Drug Fund)
  • Type: Reimbursement
  • Entries: 123
  • Diseases: 28
  • Technologies: 47
  • Companies: 21
Australia (MSAC)
  • Type: Reimbursement
  • Entries: 548
  • Diseases: 217
  • Technologies: 293
  • Companies: 123
Australia (TGA)
  • Type: Registration
  • Entries: 1367
  • Diseases: 218
  • Technologies: 528
  • Companies: 121
United States (ICER)
  • Type: Reimbursement
  • Entries: 169
  • Diseases: 36
  • Technologies: 116
  • Companies: 56
England (NICE)
  • Type: Reimbursement
  • Entries: 1056
  • Diseases: 164
  • Technologies: 395
  • Companies: 107
United States (FDA)
  • Type: Registration
  • Entries: 3260
  • Diseases: 403
  • Technologies: 1372
  • Companies: 788
Netherlands (ZiN)
  • Type: Reimbursement
  • Entries: 179
  • Diseases: 95
  • Technologies: 126
  • Companies: 75
Germany (IQWiG)
  • Type: Reimbursement
  • Entries: 1121
  • Diseases: 117
  • Technologies: 249
  • Companies: 93
Canada (CADTH)
  • Type: Reimbursement
  • Entries: 724
  • Diseases: 142
  • Technologies: 366
  • Companies: 120
Australia (PBAC)
  • Type: Reimbursement
  • Entries: 4662
  • Diseases: 253
  • Technologies: 947
  • Companies: 242
Canada (TPD)
  • Type: Registration
  • Entries: 1106
  • Diseases: 205
  • Technologies: 528
  • Companies: 168
Europe (EMA)
  • Type: Registration
  • Entries: 2248
  • Diseases: 272
  • Technologies: 771
  • Companies: 339
Canada (ERC Oncology)
  • Type: Reimbursement
  • Entries: 224
  • Diseases: 37
  • Technologies: 91
  • Companies: 39
France (TC)
  • Type: Reimbursement
  • Entries: 2259
  • Diseases: 270
  • Technologies: 734
  • Companies: 202

Powerful, flexible filters

With MAESTrO your market access and investment decisions can be better informed. Our advanced search and data filters make it easy to find, sort and analyse information that once took months to compile. Interrogate global and local market access data by:

  • Technology type
  • Technology
  • Disease
  • Patient population
  • Therapeutic area
  • Company
  • Outcome
  • Agency
  • Technology category
  • Policy issue
  • and more...

Deeper analysis

MAESTrO also provides convenient unique access to several facets of the market access record, which can add essential depth to your analysis.



Reason for rejection

Know the reason given by an HTA
for rejecting each unsuccessful submission

Timeline

See the duration of entire submission processes, to better analyse company and HTA performance.

International

Compare a new technology’s submission
progress across multiple international HTAs.

Full submission histories

Have automatic access to all resubmissions when viewing the initial submission result.